CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a objective signifier genome editing company, contiguous announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., volition contiguous astatine the 41st Annual J.P. Morgan Healthcare Conference connected Tuesday, January 10, 2023, 4:30 p.m. PT / 7:30 p.m. ET successful San Francisco, CA.
A unrecorded webcast of the presumption volition beryllium disposable connected the “Investors” conception of the Editas Medicine website astatine www.editasmedicine.com. An archived replay volition beryllium disposable connected the website for astir 30 days pursuing the presentation.
About Editas Medicine
As a objective signifier genome editing company, Editas Medicine is focused connected translating the powerfulness and imaginable of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for radical surviving with superior diseases astir the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a wide people of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent property for quality medicines. For the latest accusation and technological presentations, delight sojourn www.editasmedicine.com.
Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investors:
Ron Moldaver
(617) 401-9052
ir@editasmed.com
English (US)